Slide 1: Strategic Rationale
Strategic Rationale • Pipeline: The combination would create a diverse portfolio of clinical and near-clinical programs (approximately 10 clinical readouts expected in the next 18 months) where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion.
Slide 2: Strategic Rationale for Recursion-Exscientia Combination
Strategic Rationale for Recursion-Exscientia Combination • Pipeline: We believe that a combination with Exscientia would create a diverse portfolio of clinical and near-clinical programs (approximately 10 clinical readouts in the next 18 months) where most of these programs, if successful, could hav
Slide 3: Decoding Biology To Radically Improve Lives
Exhibit 99.3 Decoding Biology To Radically Improve Lives August 2024
Slide 4: Important Information
Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words su
Slide 5: Important Information (continued)
Important Information (continued) Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources t
Slide 6: Recursion and Exscientia Combination
Recursion and Exscientia Combination 4
Slide 7: Recursion enters agreement with Exscientia
Recursion enters agreement with Exscientia to bring better medicines to patients more rapidly and more cost efficiently Combination of Many Complementary Factors • Pipeline: Diverse portfolio of clinical and near-clinical programs with ~10 clinical readouts over the next ~18 months • Partnerships: D
Slide 8: Recursion + Exscientia: Pipeline
Recursion + Exscientia: Pipeline • Diverse Portfolio of clinical or near-clinical programs ~10 clinical readouts in the next 18 months • ~10 clinical readouts over the next ~18 months • Complementary therapeutic pipelines with no competitive overlap Combining first-in-class and best- • Most of these
Slide 9: Recursion + Exscientia: Pipeline of technology-enabled programs
Recursion + Exscientia: Pipeline of more than 10 technology-enabled programs demonstrate maturity and de-risking Anticipated Near- Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Term Milestones Topline readout Sep. 2024 REC-994 Cerebral Cavernous Malformation Superoxide SYCAMORE Preli
Slide 10: Recursion + Exscientia: Partnerships
Recursion + Exscientia: Partnerships • Diverse Portfolio of transformational partnerships with leading large pharma companies • 10 programs already optioned across oncology and immunology • Combined company expects potential additional milestone payments of ~$200 million over the next 2 years from c
Slide 11: Recursion + Exscientia: Platform
Recursion + Exscientia: Platform • Core Strengths • Recursion: scaled biology exploration and translational capabilities primarily focused on first-in- disease opportunities • Exscientia: precision chemistry design and small molecule automated synthesis primarily focused on best-in-class opportuniti
Slide 12: Exscientia capabilities integrating with the Recursion OS
Overview of areas where Exscientia’s capabilities can immediately integrate and complement the Recursion OS upon close Complementary capabilities through combination with Exscientia labelled in orange. 10
Slide 13: Summary of complementary factors
Recursion + Exscientia: Summary of complementary factors Scaled exploration and mapping of Precision chemistry design and Platform Strength biological relationships molecular synthesis First-in-class products in oncology, Best-in-class products in oncology, Internal Pipeline rare disease, infectious
Slide 14: Transaction details of Recursion-Exscientia combination
Transaction details of Recursion-Exscientia combination • Stock for stock transaction Stock • Exscientia shareholders will receive 0.7729 shares of Recursion Class A common Consideration stock for each Exscientia ordinary share, subject to rounding for fractional shares Pro-Forma • Recursion shareho
Slide 15: Exscientia: '617 precision designed to have best-in-class properties
Exscientia: ‘617 precision designed to have best-in-class properties Maximize upside potential of precision- Precision designed to maximize therapeutic index allowing for designed GTAEXS617 with purchase of full optimized combinations and potentially better efficacy rights from GT Apeiron: • Selecti
Slide 16: Recent Business Developments and Potential Milestones
Recent Business Developments and Potential Milestones 14
Slide 17: Roche-Genentech Optioned Neuroscience Phenomap for $30 Million
Roche-Genentech Optioned Industry-First Neuroscience Phenomap from Recursion for $30 Million $30 million is part of a fee structure that could exceed a total of $500 million Fee across multiple maps, not inclusive of program milestones Structure Validates Recursion’s scientific approach to mapping b
Slide 18: Value across Bayer partnership in undruggable oncology
Recursion is delivering value across its partnership with Bayer in undruggable oncology On track to complete 25 unique multi-modal data packages in Q3 Work initiated Nov 2023 Focus on Oncology Q1 Q2 Q3 Bayer is the 1st beta-user Initiated 1st Joint Project which is of LOWE (Recursion’s LLM advancing
Slide 19: REC-994 for CCM: Topline Readout in September 2024
Clinical: CCM REC-994 for CCM : Topline Readout in September 2024 SYCAMORE is the first industry-sponsored Phase 2 trial for CCM Disease & Unmet Need REC-994 Phase 2 • Cerebral Cavernous Malformation (CCM) affects ~360,000 symptomatic patients in the US and EU5 SYCAMORE Randomized, double-blind, • L
Slide 20: Pipeline – Clinical Trial Readouts Expected in ~18 Months
Milestones: Pipeline – 7 Clinical Trial Readouts Expected in ~18 Months Pipeline • CCM: Ph2 readout expected in September 2024 • NF2: Ph2 safety & preliminary efficacy expected in Q4 2024 • FAP: Ph2 safety & preliminary efficacy expected in H1 2025 • AXIN1 or APC Mutant Cancers: Ph2 safety & prelimi
Slide 21: Milestones: Partnerships and Platform
Milestones: Partnerships and Platform Partnerships Platform • Roche & Genentech: validation program option exercised for • Built our 1st genome-scale transcriptomics KO map, 1st validated hit series in oncology, 1st neuroscience moving towards multiomics foundation models phenomap optioned for $30M
Slide 22: Value Proposition and OS
Value Proposition and OS 20
Slide 23: Formula for mapping and navigating complex systems
There is a formula for mapping and navigating complex systems using technology 2 Data Aggregate and organize data to create digital maps of reality 2 Digital (bits) 3 1 Real (atoms) Algorithms 3 Navigate digital maps to Profile Systems 1 predict novel relationships, Capture high-dimensional then try
Slide 24: Data roadblocks make mapping and navigating biology difficult
Data roadblocks make mapping and navigating biology difficult Analog Standard The fax machine is alive and well in medicine, while in biopharma, study results from CROs are still often reported as PDFs or scanned printouts Siloed Data in Pharma ! Biopharma has 100s of petabytes of ! scientific data
Slide 25: Building purpose-built datasets to map and navigate biology
We are building and aggregating purpose-built datasets to map and navigate biology Data Each week we digitize millions of our own experiments across multiple layers of biology Algorithms from cell to animal Profile Systems We own and operate one of the We have built and continue to fastest supercomp
Slide 26: The Recursion OS integrates modules across drug discovery
The Recursion OS integrates modules across many diverse steps to industrialize drug discovery and development 24
Slide 27: Connecting data layers to build multiomic digital maps
We connect data layers to build multiomic digital maps of biology 25
Slide 28: Phenomics: Foundation models improve at detecting biology
2 weeks 6 months Phenomics: Foundation models improve at detecting biology DATA GENERATION MODELS Recall of biological relationships vs model size >250 million experiments 2 weeks of rapid >50 human cell types iteration on Phenom-2 0.50 candidate Biohive-2 >1 trillion neurons generated Phenom-1 enab
Slide 29: Transcriptomics: Multimodal data scales validation and mapping
Transcriptomics: Multimodal data scales validation and mapping DATA GENERATION MODELS >1M samples sequenced Replaced time-consuming, disease- 1st genome-scale transcriptomic map specific validation assays with portfolio- wide multimodal model workflow Transcriptomics IL-6 pathway 90% 60% Ability to
Slide 30: ADME: Data and scale lead to State of the Art models
ADME: Data and scale lead to State of the Art models DATA GENERATION MODELS Our single generalizable model improves with Estimated 90x throughput over manual approach multimodal data and model size >750 compounds per week Generalized performance over all 22 TDC ADMET 1.25 datasets 1.00 External best
Slide 31: InVivomics accelerates decision-making in late discovery
InVivomics accelerates decision-making in late discovery DATA GENERATION MODELS >1,000 digital mouse cages • Machine learning enables scale by extracting signals 150 digital rat cages in 2024 from video and Social housing increases relevance temperature sensors • Applied across breadth of Recursion
Slide 32: Patient Data: Path to uncover novel disease drivers
Patient Data: Path to uncover novel disease drivers with Maps DATA GENERATION MODELS >20 PB of real-world multi-modal oncology Combining data Recursion maps of biology with patient clinical Hundreds of data unlocks thousands of unique causal modeling to de-identified patient find novel targets recor
Slide 33: Shifting drug discovery from bespoke science to scaled engineering
The Recursion OS maps and navigates biology to shift drug discovery from bespoke science to scaled engineering Failing faster and earlier to › › spend less › › and go faster Recursion Industry Screen — 100 100 30 35 80% 55% 30 Hit ID — 25 80 55 25 75% 32% 20 Validated Lead — 18 20 15 60 37% 15 Advan
Slide 34: Our unique approach creates novel opportunities
Our unique approach creates novel opportunities Recursion’s Approach High potential, Low potential, unexplored unexplored Low potential, High potential, thoroughly explored thoroughly explored 32
Slide 35: Multi-pronged capital efficient business strategy
We harness value from the Recursion OS with a multi-pronged capital efficient business strategy Pipeline Strategy Precision Oncology Build internal pipeline in indications with potential for Rare Disease accelerated path to approval Pipeline Partnership Strategy Neuroscience* Partner in complex ther
Slide 36: Value Creation – Pipeline
Value Creation – Pipeline 34
Slide 37: Multi-pronged business strategy: Pipeline
We harness value from the Recursion OS with a multi-pronged capital efficient business strategy Pipeline Strategy Precision Oncology Build internal pipeline in indications with potential for Rare Disease accelerated path to approval Pipeline Partnerships Data *Includes a single oncology indication f
Slide 38: Our pipeline reflects the scale and breadth of our approach
Our pipeline reflects the scale and breadth of our approach Anticipated Patient Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Near-Term Population Milestones Topline readout in 1 REC-994 Cerebral Cavernous Malformation Superoxide ~ 360K SYCAMORE September 2024 Preliminary data 2 POPL
Slide 39: SYCAMORE Clinical Trial: REC-994 for CCM Phase 2 Fully Enrolled
Clinical: CCM SYCAMORE Clinical Trial : REC-994 for CCM Phase 2 Fully Enrolled CAUSE PREVALENCE & STANDARD OF CARE LOF mutations in genes CCM1, CCM2 & CCM3, key for Symptomatic US + EU5, maintaining the structural integrity of the vasculature due to >1 million patients worldwide unknown mechanisms ~
Slide 40: SYCAMORE Trial Design: REC-994 for CCM
Clinical: CCM SYCAMORE Clinical Trial: REC-994 for CCM Phase 2 Fully Enrolled Topline Data Expected September 2024 Screening & Randomization 1:1:1 Treatment Follow-up Enrollment Criteria • MRI-confirmed CCM lesion(s) • Familial or sporadic • Symptoms directly related to CCM 400mg Outcome Measures Ex
Slide 41: REC-994 for CCM: Expectations
Clinical: CCM REC-994 for CCM: Expectations Outcome Measures Trial Update • Primary: Safety and Tolerability • Enrollment is complete • Adverse events & symptoms • Vast majority of participants who completed 12 months of treatment continue to enter long- • Secondary & Exploratory: term extension • E
Slide 42: POPLAR Trial: REC-2282 for NF2
Clinical: NF2 POPLAR Trial: REC-2282 for NF2 Part A Fully Enrolled CAUSE PREVALENCE & STANDARD OF CARE LOF mutations in NF2 tumor suppressor gene, leading to deficiencies in the tumor suppressor protein merlin Treatable US + EU ~33,000 No approved therapy PATHOPHYSIOLOGY & REASON TO BELIEVE • Surger
Slide 43: POPLAR Trial Design: REC-2282 for NF2
Clinical: NF2 POPLAR Trial: REC-2282 for NF2 Part A Fully Enrolled Phase 2/3 trial initiated in Q2 2022 Key Enrollment Criteria • MRI-confirmed progressive Phase 2 portion meningioma 40 mg TIW • Sporadic meningioma with ~6 Sporadic ~6 Familial confirmed NF2 mutation 6-month PFS FDA Mtg • Familial NF
Slide 44: TUPELO Clinical Trial: REC-4881 for FAP
Clinical: FAP TUPELO Clinical Trial : REC-4881 for FAP Phase 2 Underway CAUSE PREVALENCE & STANDARD OF CARE Inactivating mutations in the tumor suppressor gene APC Diagnosed US + EU ~50,000 PATHOPHYSIOLOGY & REASON TO BELIEVE No approved therapy Polyps throughout the GI tract with • Colectomy during
Slide 45: TUPELO Trial Design: REC-4881 for FAP
Clinical: FAP TUPELO Clinical Trial : REC-4881 for FAP Phase 2 Underway Part 2 Enrollment Commenced Screening & Treatment Key Enrollment Criteria • Confirmed APC mutation Part 2 • ≥ 55 years old • Post-colectomy/proctocolectomy Single agent REC-4881 • No cancer present Dose Expansion Recommended Dos
Slide 46: LILAC Clinical Trial: REC-4881 for AXIN1 or APC mutant cancers
Clinical: AXIN1 or APC LILAC Clinical Trial: REC-4881 for AXIN1 or APC mutant cancers CAUSE PREVALENCE & STANDARD OF CARE LOF mutations in AXIN1 or APC tumor suppressor genes Treatable US + EU ~104,000 PATHOPHYSIOLOGY & REASON TO BELIEVE Substantial need for developing therapeutics for Alterations i
Slide 47: LILAC Trial Design: REC-4881
Clinical: AXIN1 or APC LILAC Clinical Trial: REC-4881 for AXIN1 or APC mutant cancers FPI achieved Q1 2024 Screening & Treatment Enrollment Criteria • Unresectable, locally advanced, or Part 1 Part 2 metastatic cancers • ≥ 55 years old • AXIN1 or APC mutation confirmed by NGS AXIN1 AXIN1 Futility As
Slide 48: ALDER Clinical Trial: REC-3964 for C. Difficile
Clinical: C. difficile ALDER Clinical Trial: REC-3964 for C. Difficile PREVALENCE & STANDARD OF CARE TREATMENT PARADIGM • Standard of care for Diagnosed US 1st occurrence: Antibiotics alone + EU5 patients ~730,000 • Recurrence (20-30% of patients) treated • Severity of infection varies and can range
Slide 49: ALDER Trial Design: REC-3964
Clinical: C. difficile ALDER Clinical Trial: POC Phase 2 REC-3964 in Patients at High Risk of C. Difficile Recurrence Screening Randomization & Treatment Enrollment Criteria • Patients at high risk of recurrence REC-3964 500 mg orally BID • ≥3 bowel movements in 24 hours • Confirm CDI using EIA (tox
Slide 50: REC-1245: RBM39 Inhibition for Advanced HR-Proficient Cancers
Preclinical: REC-1245 REC-1245: RBM39 Inhibition for Advanced HR-Proficient Cancers Identify tumor-targeted precision therapeutic NCE with novel MOA capable GOAL of potentially treating HR-proficient cancers CDK12 Inhibition of target RBM39 (previously referred to as Target γ) may mimic the Similar
Slide 51: REC-1245: Planned Phase 1/2 study
Preclinical: REC-1245 REC-1245: RBM39 Inhibition for Advanced HR-Proficient Cancers Planned Phase 1/2 study of REC-1245 in Biomarker Selected R/R HR-Proficient Solid Tumors Phase 1A Phase 1B Phase 2 Dose Finding Dose Confirmation N=10-30 (Accelerated Titration BOIN) N=20 N=30 N = 3-6 Using BOIN Dose
Slide 52: Target Epsilon: Novel Approach for Fibrotic Diseases
Preclinical: Undisclosed Indication in Fibrosis Target Epsilon: Novel Approach for Fibrotic Diseases Reversal of Fibrocyte Differentiation Assay Identify a therapeutic NCE with a novel MOA capable of reversing disease- GOAL related fibrotic processes Recursion-generated hits show concentration-depen
Slide 53: Value Creation – Partnerships
Value Creation – Partnerships 51
Slide 54: Multi-pronged business strategy: Partnerships
We harness value from the Recursion OS with a multi-pronged capital efficient business strategy Pipeline Partnership Strategy Neuroscience* Partner in complex therapeutic areas Undruggable Oncology requiring large financial commitment or competitive arbitrage Partnerships Other large, intractable ar
Slide 55: Scientific collaborations span biopharma, tech & data
Exciting scientific collaborations span biopharma, tech & data Therapeutic discovery Platform, Technology and Data Neuroscience and a single oncology indication Computation and ML/AI • $50M equity investment • Partnership on advanced computation (e.g., foundation model development) • $150M upfront a
Slide 56: Value Creation – Data Strategy
Value Creation – Data Strategy 54
Slide 57: Multi-pronged business strategy: Data
We harness value from the Recursion OS with a multi-pronged capital efficient business strategy Pipeline Partnerships Data Strategy Licensing License subsets of data and key tools Augment Recursion OS Direct generation of new data Data internally to maximize pipeline and partnership value-drivers *I
Slide 58: The Recursion OS is a palette of evolving modules
The Recursion OS is a palette of evolving sophisticated modules 56
Slide 59: LOWE puts the Recursion OS at your fingertips
LOWE puts the Recursion OS at your fingertips via natural language without any coding expertise required [ DEMO ] 57
Slide 60: LOWE puts the Recursion OS at your fingertips (demo)
LOWE puts the Recursion OS at your fingertips via natural language without any coding expertise required [ DEMO ] 58
Slide 61: Recursion OS accessible via a Discovery User Interface
The Recursion OS is now more than a collection of point solutions accessible to expert users …it is increasingly integrated and accessible via a Discovery User Interface that can be used by any of our scientists from the comfort of their laptop… 59
Slide 62: Culture and Team
Culture and Team 60
Slide 63: Our People
Our People Functional Breakdown Locations >500 employees Montréal, Québec Technology – data science, software engineering, Toronto, Ontario >50% automation, etc. have advanced Salt Lake City, Life Sciences – biology, Utah degrees San Francisco, chemistry, development, etc. California Strategic Opera
Slide 64: Our leadership brings together experience & innovation
Our leadership brings together experience & innovation to advance TechBio Board of Directors Dean Li, MD PHD Zavain Dar Chris Gibson, PHD Rob Hershberg, MD PHD Co-Founder of RXRX, Co-Founder & Partner Co-Founder & CEO Co-Founder, CEO, & Chair President of Merck Research of Dimension of HilleVax, For
Slide 65: Additional Information about Scientific Approach
Additional Information about Scientific Approach 63
Slide 66: Genome-scale mapping
Genome-scale mapping This is a whole-genome arrayed CRISPR knock-out Map generated in primary human endothelial cells Every gene is represented in a pairwise way (each is present in columns and rows) Dark Red indicates phenotypic similarity according to our neural networks while Dark Blue indicates
Slide 67: JAK / STAT pathway clustered by strength of interaction
DOCK9 SLC39A1 ASB7 MEGF8 PRKCH SOCS3 PHF13 PPP1R9B TNKS1BP1 ZMYM3 FAM49B STK24 YWHAB IL6ST IL6R STAT3 IL6 JAK1 One such example – the JAK / STAT pathway clustered by strength of interaction, including both similar genes (red) and opposite genes (blue) Can wade into areas of novel biology and chemist
Slide 68: AI Strategy Experiments @ Recursion
Al Strategy Experiments @ Recursion
Slide 69: Virtuous Cycles Drive Super-Linear Knowledge Creation
Virtuous Cycles Drive Super-Linear Knowledge Creation 67
Slide 70: Additional Information about Pipeline Programs
Additional Information about Pipeline Programs 68
Slide 71: REC-994 for CCM: First-in-disease potential
Clinical: CCM REC-994 for CCM First-in-disease potential in CCM with an orally bioavailable small molecule superoxide scavenger • First therapeutic candidate advanced to an industry-sponsored Phase 2 trial (SYCAMORE) for CCM Program • Partnered with leading KOLs at University of Rochester to develop
Slide 72: CCM is an Under-Appreciated Orphan Disease
Clinical: CCM 70 Disease Overview : CCM is an Under-Appreciated Orphan Disease Non-oncology Orphan Indication Product U.S. + EU5 Prevalence >1,800,000 Cerebral cavernous malformation (CCM) REC-994 (Recursion) (Symptomatic: ~360,000) Idiopathic pulmonary fibrosis (IPF) Esbriet (pirfenidone) >160,000
Slide 73: CCM – Applied prototyping of the Recursion OS
Clinical: CCM CCM – Applied prototyping of the Recursion OS siCTRL siCCM2 siCCM2 + REC-994 siCCM2 + Simvastatin siCCM2 + Cholecalciferol Using an early version of our Recursion OS in an academic setting, we identified about 39 molecules out of 2,100 screened that according to a machine learning clas
Slide 74: REC-994 reduces lesion burden in genetic mouse models of CCM
Clinical: CCM Preclinical Studies: REC-994 reduces lesion burden and ameliorates vascular defects in genetic mouse models of CCM Reduces lesion number & size in Ccm1 and Ccm2 LOF mouse models 1 Ccm1 LOF Model Ccm2 LOF Model * * * 2 2 Lesion size (mm ) Lesion size (mm ) Rescues acetylcholine-induced
Slide 75: REC-994: Mechanism of Action
Clinical: CCM REC-994 : Mechanism of Action Healthy REC-994 Impact CCM CCM1 or CCM2 loss of function leads By regulating SOD2, CCM1 (KRIT1) & Dosing of REC-994 restores to activated endothelium: CCM2 suppress: normal function: • Endothelial cell activation • Decreased cell-cell junctional • Normaliz
Slide 76: Clinical Studies Indicate Favorable Safety Profile
Clinical: CCM Further Confidence : Clinical Studies Indicate Favorable Safety Profile REC-994 Phase 1 Studies - well-tolerated with no dose-dependent adverse events in SAD and MAD MAD Study Placebo 50 mg 200 mg 400 mg 800 mg Total Number of TEAEs 5 0 10 4 15 Total Subjects with ≥ one TEAE 4 0 3 3 4
Slide 77: REC-2282 for Neurofibromatosis Type 2 (NF2)
Clinical: NF2 REC-2282 for Neurofibromatosis Type 2 (NF2) First-in-disease opportunity in NF2 with HDAC inhibitor • Orally bioavailable small molecule inhibitor of class I and class IIB HDACs in Phase 2/3 (POPLAR) trial Program • Unique MOA that disrupts PP1-HDAC interface, attenuating pathophysiolo
Slide 78: Neurofibromatosis Type 2 Meningiomas Disease Overview
Clinical: NF2 76 Disease Overview : Neurofibromatosis Type 2 (NF2) Meningiomas • Most tumors are benign and slow growing but location in CNS leads to serious morbidity or mortality • Prognosis is adversely affected by early age at onset, a higher number of meningiomas and having a truncating mutatio
Slide 79: REC-2282 Rescued Loss of NF2
Clinical: NF2 77 Insight from OS : REC-2282 Rescued Loss of NF2 Prevents growth & regrowth of NF2- deficient meningioma model in mice REC-2282 Healthy NF2 knockdown Cells cells + REC-2282 (months) + Normal diet (months) HUVEC, human umbilical vein endothelial cells; NF2, neurofibromatosis type 2; si
Slide 80: REC-2282: Mechanism of Action
Clinical: NF2 78 REC-2282 : Mechanism of Action Orally Bioavailable, CNS-penetrating, Small Molecule HDAC Inhibitor 1 2 3 1 2 3 NF2 encodes for the protein 1 Merlin and negatively regulates mTOR signaling Constitutive activation is independent of extracellular factors and does not respond to biochem
Slide 81: REC-2282 vs Other HDAC Inhibitors
Clinical: NF2 79 REC-2282 Appears Well Suited for NF2 vs Other HDAC Inhibitors REC-2282 Would be First-In-Disease HDAC Inhibitor for Treatment of NF2 Meningiomas 1 Sborov DW, et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lympho
Slide 82: REC-4881 for Familial Adenomatous Polyposis (FAP)
Clinical: FAP REC-4881 for Familial Adenomatous Polyposis (FAP) First-in-disease opportunity in FAP with a MEK 1/2 inhibitor • Orally bioavailable, small molecule non-ATP competitive allosteric inhibitor of MEK 1/2 in Phase 1b/2 (TUPELO) Program • REC-4881 appears more active versus approved MEK inh
Slide 83: Familial Adenomatous Polyposis Disease Overview
Clinical: FAP 81 Disease Overview : Familial Adenomatous Polyposis Patient Population • Autosomal dominant tumor predisposition syndrome caused by a mutation in the APC gene • Classic FAP (germline mutation) : • Hundreds to thousands of polyps in colon and upper GI tract • Extraintestinal manifestat
Slide 84: Preclinical Validation of OS Insight in FAP Models
Clinical: FAP Preclinical Validation of Novel OS Insight in Relevant FAP Models 82
Slide 85: REC-4881 Blocks Wnt Mutation Induced MAPK Signaling
Clinical: FAP 83 MoA : REC-4881 Blocks Wnt Mutation Induced MAPK Signaling Orally Bioavailable, Small Molecule MEK Inhibitor Disease State REC-4881 Impact 1 3 2 REC-4881 inhibits MEK 1/2 and recovers the destabilization of RAS by the 3 β-Catenin destruction complex, restoring the cell back to a Wnt-
Slide 86: REC-4881 for AXIN1 or APC Mutant Cancers
Clinical: AXIN1 or APC REC-4881 for AXIN1 or APC Mutant Cancers First-in-disease opportunity in AXIN1 or APC mutant cancers with a MEK 1/2 inhibitor • Orally bioavailable, small molecule non-ATP competitive allosteric inhibitor of MEK 1/2 in Phase 2 (LILAC) Program • First therapeutic candidate adva
Slide 87: AXIN1 or APC Mutant Cancers Disease Overview
Clinical: AXIN1 or APC 85 Disease Overview : AXIN1 or APC Mutant Cancers Breast Gynecological 4% 7% Flexible Patient Selection Strategy and Study Design • AXIN1 and APC genes covered by commercially available NGS Urological 3 Colorectal 13% panels and liquid biopsy detection assays 42% • FDA guidanc
Slide 88: Recursion OS Identified Novel Insight of AXIN1 & APC biology
Clinical: AXIN1 or APC 86 Recursion OS Identified Novel Insight of AXIN1 & APC biology REC 4881 Significantly greater antitumor activity in mutant models led to significant PFS benefit APC AXIN1 2.5 µm 1.0 µm 0.25 µm 0.1 µm REC-4881 is phenotypically opposite to the genetic KO of APC and AXIN1 provi
Slide 89: REC-3964 for Prevention of recurrent C. difficile infection
Clinical: C. difficile REC-3964 for Prevention of recurrent C. difficile infection (rCDI) Potential first-in-class small molecule for prevention of rCDI • Orally bioavailable, small molecule C. difficile toxin inhibitor and the first NCE developed by Recursion Program • Differentiated MOA selectivel
Slide 90: REC-3964 Rescued Cells Treated with C. difficile Toxins
Clinical: C. difficile Insight from OS: REC-3964 Rescued Cells Treated with C. difficile Toxins REC-3964 significantly extended survival over SOC REC-3964 0.1 µM Disease State Healthy • REC-3964 potently inhibits toxin B with residual activity against Cells toxin A, while bezlotoxumab is specific to
Slide 91: REC-3964: Selective Inhibitor of C. difficile Toxins
Clinical: C. difficile REC-3964 : Selective Inhibitor of C. difficile Toxins REC-3964 is Recursion’s 1st Small Molecule NCE to Reach the Clinic 1 CDI toxins bind to cell surface receptors and 1 trigger endocytic event Autocatalytic cleavage event releases CDI 2 toxin's glucosyltransferase enzymatic
Slide 92: REC-3964: Selective Inhibitor of C. difficile Toxins
Clinical: C. difficile REC-3964 : Selective Inhibitor of C. difficile Toxins REC-3964 is Recursion’s 1st Small Molecule NCE to Reach the Clinic 1 2 5 3 REC-3964 binds and blocks 5 catalytic activity of the toxin’s innate glucosyltransferase, but not 4 the host's 90 Adapted from Awad, MM. et al. (201
Slide 93: REC-3964 Phase 1 Study Complete
Clinical: C. difficile 91 REC-3964 for C. difficile Phase 1 Study Complete Phase 1 Topline Trial Design • Randomized, Double-blind Trial • REC-3964 oral administration was well tolerated by all subjects tested Population ✓ 3% (n=1) of participants in SAD with drug-related AEs • Healthy Participants
Slide 94: Clinical Studies Confirming Safety
Clinical: C. difficile Further Confidence : Clinical Studies Confirming Safety REC-3964 was well-tolerated with no treatment-related SAEs REC-3964 MAD Placebo 100 mg 300 mg 500 mg 900 mg Overall Overall MAD Study (N=8) (N=10) (N=8) (N=8) (N=8) (N=34) (N=42) n ( %) n ( %) n ( %) n ( %) n ( %) n ( %)
Slide 95: REC-1245: RBM39 Inhibition for Advanced HR-Proficient Cancers
Preclinical: REC-1245 REC-1245: RBM39 Inhibition for Advanced HR-Proficient Cancers Potential first-in-class molecular glue degrader for biomarker selected population • Recursion OS identified RBM39 as a novel target capable of mimicking CDK12 biology independent of CDK13 Program • Lead molecule has
Slide 96: Recursion
Recurs ion. Learnings) Call
Slide 97: Important Information
Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words su
Slide 98: Important Information (continued)
Important Information (continued) Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources t
Slide 99: Recursion and Exscientia Combination
Recursion and Exscientia Combination 4
Slide 100: Recursion enters agreement with Exscientia
Recursion enters agreement with Exscientia to bring better medicines to patients more rapidly and more cost efficiently Combination of Many Complementary Factors • Pipeline: Diverse portfolio of clinical and near-clinical programs with ~10 clinical readouts over the next ~18 months • Partnerships: D
Slide 101: Recursion + Exscientia: Pipeline
Recursion + Exscientia: Pipeline • Diverse Portfolio of clinical or near-clinical programs ~10 clinical readouts in the next 18 months • ~10 clinical readouts over the next ~18 months • Complementary therapeutic pipelines with no competitive overlap Combining first-in-class and best- • Most of these
Slide 102: Recursion + Exscientia: Pipeline of technology-enabled programs
Recursion + Exscientia: Pipeline of more than 10 technology-enabled programs demonstrate maturity and de-risking Anticipated Near- Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Term Milestones Topline readout Sep. 2024 REC-994 Cerebral Cavernous Malformation Superoxide SYCAMORE Preli
Slide 103: Recursion + Exscientia: Partnerships
Recursion + Exscientia: Partnerships • Diverse Portfolio of transformational partnerships with leading large pharma companies • 10 programs already optioned across oncology and immunology • Combined company expects potential additional milestone payments of ~$200 million over the next 2 years from c
Slide 104: Recursion + Exscientia: Platform
Recursion + Exscientia: Platform • Core Strengths • Recursion: scaled biology exploration and translational capabilities primarily focused on first-in- disease opportunities • Exscientia: precision chemistry design and small molecule automated synthesis primarily focused on best-in-class opportuniti
Slide 105: Exscientia capabilities integrating with the Recursion OS
Overview of areas where Exscientia’s capabilities can immediately integrate and complement the Recursion OS upon close Complementary capabilities through combination with Exscientia labelled in orange. 10
Slide 106: Summary of complementary factors
Recursion + Exscientia: Summary of complementary factors Scaled exploration and mapping of Precision chemistry design and Platform Strength biological relationships molecular synthesis First-in-class products in oncology, Best-in-class products in oncology, Internal Pipeline rare disease, infectious
Slide 107: Transaction details of Recursion-Exscientia combination
Transaction details of Recursion-Exscientia combination • Stock for stock transaction Stock • Exscientia shareholders will receive 0.7729 shares of Recursion Class A common Consideration stock for each Exscientia ordinary share, subject to rounding for fractional shares Pro-Forma • Recursion shareho
Slide 108: Exscientia: '617 precision designed to have best-in-class properties
Exscientia: ‘617 precision designed to have best-in-class properties Maximize upside potential of precision- Precision designed to maximize therapeutic index allowing for designed GTAEXS617 with purchase of full optimized combinations and potentially better efficacy rights from GT Apeiron: • Selecti
Slide 109: Recursion Business Developments and Potential Milestones
Recursion Business Developments and Potential Milestones 14
Slide 110: Roche-Genentech Optioned Neuroscience Phenomap for $30 Million
Roche-Genentech Optioned Industry-First Neuroscience Phenomap from Recursion for $30 Million $30 million is part of a fee structure that could exceed a total of $500 million Fee across multiple maps, not inclusive of program milestones Structure Validates Recursion’s scientific approach to mapping b
Slide 111: Value across Bayer partnership in undruggable oncology
Recursion is delivering value across its partnership with Bayer in undruggable oncology On track to complete 25 unique multi-modal data packages in Q3 Work initiated Nov 2023 Focus on Oncology Q1 Q2 Q3 Bayer is the 1st beta-user Initiated 1st Joint Project which is of LOWE (Recursion’s LLM advancing
Slide 112: REC-994 for CCM: Topline Readout in September 2024
Clinical: CCM REC-994 for CCM : Topline Readout in September 2024 SYCAMORE is the first industry-sponsored Phase 2 trial for CCM Disease & Unmet Need REC-994 Phase 2 • Cerebral Cavernous Malformation (CCM) affects ~360,000 symptomatic patients in the US and EU5 SYCAMORE Randomized, double-blind, • L
Slide 113: Pipeline – Clinical Trial Readouts Expected in ~18 Months
Milestones: Pipeline – 7 Clinical Trial Readouts Expected in ~18 Months Pipeline • CCM: Ph2 readout expected in September 2024 • NF2: Ph2 safety & preliminary efficacy expected in Q4 2024 • FAP: Ph2 safety & preliminary efficacy expected in H1 2025 • AXIN1 or APC Mutant Cancers: Ph2 safety & prelimi
Slide 114: Milestones: Partnerships and Platform
Milestones: Partnerships and Platform Partnerships Platform • Roche & Genentech: validation program option exercised for • Built our 1st genome-scale transcriptomics KO map, 1st validated hit series in oncology, 1st neuroscience moving towards multiomics foundation models phenomap optioned for $30M
Slide 115: Recursion
Recursion. Learnings) Call